Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)

Monotherapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) still leads to incomplete responses in most EGFR-mutation positive non-small cell lung cancer (NSCLC) patients, often due to acquired resistance through activation of parallel compensatory pathways. We have pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bracht, Jillian Wilhelmina Paulina, Karachaliou, Niki, Berenguer, Jordi, Pedraz-Valdunciel, Carlos, Filipska, Martyna, Codony-Servat, Carles, Codony-Servat, Jordi, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854375/
https://www.ncbi.nlm.nih.gov/pubmed/31754333
http://dx.doi.org/10.7150/ijbs.32889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854375/
https://www.ncbi.nlm.nih.gov/pubmed/31754333
http://dx.doi.org/10.7150/ijbs.32889

Ejemplares similares